Associations of plasma fibrinogen assays, C-reactive protein and interleukin-6 with previous myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 11, 2003, Pages 2312-2316

  Lowe, G D O ^a   Woodward, M ^b   Rumley, A ^a   Morrison, C E ^c   Nieuwenhuizen, W ^d  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^d TNO   (Netherlands)

Author keywords

fibrinogen; Inflammation; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6;

ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; SURVIVOR;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SURVIVORS;

EID: 3042725991     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00467.x     Document Type: Article

References (34)

1. Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death; early results of a prospective study. Lancet 1980; i: 1050-4.
2. Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relationship between extent of coronary artery disease and blood viscosity. BMJ 1980; i: 673-4.
3. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor, a meta-analysis and review ofthe literature. Ann intern Med 1993; 118: 956-63.
4. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle aged men and women - The Scottish Heart Health Study. Eur Heart J 1998; 19: 55-62.
5. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C- reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analysis of prospective studies. JAMA 1998; 279: 1477-82.
6. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. Arterioscler Thromb Vase Biol 1999; 19: 1368-77.
7. McCallum PK, Meade TW. Haemostatic function, arterial disease and the prevention of arterial thrombosis. Baillière's Clin Haematol 1999; 12: 577-99.
8. Humphries SE, Henry JA, Montgomery HE. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinol 1999; 10: S17-S21.
9. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
10. Youngman L, Keavney B, Palmer A, Parish S, Clark S, Danesh J, Delepine M, Lathrop M, Peto R, Collins R. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by 'Mendelian' randomisation. Circulation 2000; 102 (Suppl. II):31-2.
11. Nieuwenhuizen W Biochemistry and measurement of fibrinogen. Eur Heart J 1995; 16 (Suppl. A): 6-10.
12. Von Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17: 237-46.
13. Givens T, Fischer TJ, Swan R. MDA™180 Methods/or the Determina tion of Fibrinogen Concentration. Durham, NC: Organon Teknika, 1995.
14. Rossi E, Mondonica P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res 1988; 52: 452-68.
15. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp (a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
16. Hoegee-de Nobel E, Voskuilen M, Briet E, Brommer EJ, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immuno-assay for the determination of plasma fibrinogen concentrations. Thromb Haemost 1988; 60: 415-8.
17. Seifried E, Oethinger M, Tanswell P, Hoegee-de Nobel E, Nieuwenhuizen W. Studies of the functionality of fibrinogen during rt-PA therapy: results of three different methods of fibrinogen determination. Blood Coagul Fibrinolysis 1992; 3: 81-7.
18. Oethinger M, Tanswell P, Hoegee-de Nobel E. Verleuaf von zirkulierendem Fibrinogen beim akuten Myokardinfarkt unter trombolytischer Therapie mit rt-PA. Lab Med 1994; 18: 62-71.
19. Hofmann JJML, Vijgen M, Nieuwenhuizen W. Comparison of the specificity of four fibrinogen assays during thrombolytic therapy. Fibrinolysis 1990; 4 (Suppl. 2): 121-3.
20. Reganon E, Vila V, Aznar J, Lacueva V, Martinez V, Ruano M. Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increases in the rate of fibrinopeptide release. Thromb Haemost 1993; 70: 978-83.
21. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G. A case control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992; 12: 701-7.
22. Morrison C, Woodward M, Leslie W, Tunstall-Pedoe H. Effect of socio-economic group on incidence of, management of, and survival after myocardial infarction and coronary death: analysis of community coronary event register. BMJ 1997; 314: 541-6.
23. Tunstall-Pedoe H, for the WHO MONICA Project. The World Health Organisation MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol 1988; 41: 105-13.
24. Lowe GDO, Yarnell JWG, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-Dimer, and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vase Biol 2001; 21: 603-10.
25. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999; 104: 246-57.
26. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70: 213-20.
27. Palareti G, Maccaferri M, Manotti C, Tripodi A, Chantarangkul V, Rodeghiero F, Ruggeri M, Mannucci PM. Fibrinogen assays; a collaborative study of six different methods. Clin Chem 1991; 37: 714-9.
28. Chitolie A, Mackie IJ, Grant D, Hamilton JL, Machin SM. Inaccuracy of the 'derived' fibrinogen measurement. Blood Coagul Fibrinolysis 1994; 5: 955-7.
29. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
30. Danesh J, Muir J, Wong Y-K, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999; 20: 954-9.
31. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW C-reactive protein in healthy subjects, associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vase Biol 1999; 19: 972-8.
32. Hak AE, Stehouwer CDA, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vase Biol 1999; 19: 1986-91.
33. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein, relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-90.
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.